NetComposites Ltd has transferred the rights and ownership of this website to Gardner Business Media Inc.
On 1st January 2020, NetComposites' media assets including netcomposites.com, newsletters and conferences were transferred to Composites World (Gardner Business Media).
This site is no longer being updated. Please direct all enquiries to firstname.lastname@example.org.
For further details see our joint press release.
As a wholly owned subsidiary of Prodesco, Secant Medical will offer its customers in the medical device and biotechnology industries dedicated resources for the design, development and manufacture of engineered fabric and composite structures.
Prodesco will continue to focus on the needs of industrial markets. “”Prodesco’s Medical Division has enjoyed significant growth over the past few years and now has an excellent worldwide reputation for supplying component structures for medical implant applications. With the launch of Secant Medical, the company will continue to be the premier developer and supplier of engineered components for use in the demanding and expanding field of Class III implants,”” stated Steve Chadwick, President and CEO of Secant Medical.
For over 35 years, Prodesco’s medical division has been manufacturing OEM class III implants for its customers, concentrating on items such as vascular grafts, implantable meshes, adhesion barriers, heart valve components, scaffold structures and stents. This will form the core of Secant Medical’s growing business.
Tom Molz, COO, commented, “”The establishment of Secant Medical will provide our customers dedicated, experienced resources and an even greater focus to solve the clinical needs of the medical community.””
“”The key to our success has been our ability to provide innovative and proprietary solutions for our customers’ challenging design issues, adding value to the end product. We have extensive experience with numerous biocompatible, bio-absorbable and metallic fibers for many types of medical devices,”” added Dr. Skott Greenhalgh, VP and CTO.
For more information visit: